TRIAL DETAIL
IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 05/01/2008 |
Age of Trial (yrs) 16.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor + mTOR Inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
2007-0595 |
|||
Sponsor: |
M.D. Anderson Cancer Center
National Cancer Institute (NCI) |
|||
Patient Contact: |
Aung Naing, MD
713-563-0181 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Primary Objectives: * To evaluate the safety and tolerability; and to determine maximum tolerated dose (MTD) of the combination of IMC-A12 with temsirolimus in patients with or without biopsiable advanced cancers. * To evaluate the biologic effect of each individual drug and this drug combination on expression/phosphorylation of potential markers of response in patients with biopsiable disease. * To assess tumor metabolism by Positron Emission Tomography (PET). Secondary Objectives: * To report the clinical tumor response of this combination in a descriptive fashion. |
|||
Trial Links |
Trial Results |
Drug Information |
| CCI-779 (temsirolimus) in Wikipedia |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
4100 John R |
Detroit |
MI |
48201 |
USA |